If you were among the few that missed Biotech Week Boston 2017 then you missed a lot. The event, in its second year, was jam packed with insightful sessions, rooms filled with scientists, pharma innovators, sponsors and exhibitors.
We’ve gathered some of the best photos from BWB to recap the four-day event that ran September 25th through September 28th, 2017.
The keynote speakers, J Craig Venter, Flemming Ornskov, James J. Collins, Dean K. Pettit and Tyler Jacks took to the main stage to share insightful data and new developments in bioprocessing and cell and gene therapy.
Continue reading “Biotech Week Boston 2017 in Photos”
Preuse post-sterilization integrity testing (PUPSIT) is recommended by most regulators for critical sterilizing liquid filters used in aseptic processing. A preuse test before sterilization will confirm that a filter is installed properly and was not damaged during shipment or handling. Performing a preuse test afterward can detect damage from the sterilization cycle itself. That can limit risk, making it current industry practice especially for products marketed in the European Union. But such testing can be difficult without breaching system sterility.
Continue reading “Preuse Post-Sterilization Integrity Testing Best Practices”
What do you see as the next generation of changes in the industry?
There’s diversity in the product pipeline, the portfolio difference and different types of therapies being developed, from biosimilars to antibody drug conjugates, gene and cell therapies, and how the manufacturers will respond to them is a key challenge.
So some of the themes we’re hearing about are single use technologies, process integration, and then evolving into continuous manufacturing. There are also regulatory, manufacturing and scientific challenges in this area that need to be addressed.
What challenges are you seeing with companies who work with you?
There’s a broad range of challenges, people want to stay current with the latest technologies, and being compliant with the regulatory requirements. There’s also the challenge of manufacturing complex therapies. So it’s quite a dynamic environment, and there is further challenges in keeping staff current and up to date with the latest scientific developments is always a challenge and an opportunity
How can NIBRT address these requirements?
NIBRT’s role is to help the growth and development of the biotech sector in Ireland and internationally. We do that in two ways, by conducting training programmes and also by conducting applied research programmes to help both the manufacturers, academic communities and vendor communities. This way, we aim to make biopharmaceutical manufacturing as efficient and as effective as possible.